YNK 01

Known as: YNK-01 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2003
01219892003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
There are two kinds of beta-oxidation systems of fatty acids in mitochondria and peroxisomes in animal liver cells. These beta… (More)
Is this relevant?
2001
2001
BACKGROUND AND OBJECTIVES Subcutaneous Ara-C plus interferon (IFN) produces more cytogenetic responses than IFN in chronic… (More)
Is this relevant?
2001
2001
FRANCISCO CERVANTES, ANNA SUREDA,* JUAN-CARLOS HERNÁNDEZ-BOLUDA, RODRIGO MARTINO,* SALUT BRUNET,* DANIEL BORREGO,° JOSÉ LUIS… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
1998
1998
Twenty-three patients with hepatocellular carcinoma (HCC) were enrolled in this cooperative study conducted in Hirosaki… (More)
Is this relevant?
1997
1997
Thirty-two patients with hepatocellular carcinoma (HCC) were treated with YNK-01, a prodrug of cytarabine for oral administration… (More)
Is this relevant?
1995
1995
Ara-CMP-Stearate (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, YNK 01, Fosteabine) is the orally applicable prodrug of… (More)
Is this relevant?
1991
1991
 
Is this relevant?
1989
1989
 
Is this relevant?